Literature DB >> 25271000

Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

Maeve P Crowley, Maeve P Crowely1, Shane Quinn, Eoin Coleman, Joseph A Eustace, Oonagh M Gilligan, Susan I O'Shea, Susan I O Shea.   

Abstract

The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. There is little data with regard to changes in thromboelastography in patients with myeloma or MGUS. The aim of this study was to investigate the differing coagulation profiles of patients of patients with myeloma and MGUS by means of conventional coagulation tests and thromboelastography. Blood was taken by direct venepuncture from patients with myeloma, MGUS and normal controls. Routine coagulation tests were performed in an accredited hospital laboratory. Thromboelastography (TEG(®)) was performed as per the manufacturer's protocol. Eight patients were recruited in each group. Patients with myeloma had a significantly lower mean haemoglobin level than patients with MGUS or normal controls (p < 0.001). Patients with myeloma had a significantly more prolonged mean prothrombin time than normal controls (p = 0.018) but not patients with MGUS. Patients with myeloma had significantly higher median D-dimer levels than normal controls (p = 0.025), as did patients with MGUS (p = 0.017). Patients with myeloma had a significantly higher mean factor VIII level than normal controls (p = 0.009) and there was a non-significant trend towards patients with MGUS having higher factor VIII levels than normal controls (p = 0.059). There was no significant difference in thromboelastographic parameters between the three groups. Patients with MGUS appear to have a distinct coagulation profile which is intermediate between patients with myeloma and normal controls.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25271000     DOI: 10.1007/s11239-014-1140-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  30 in total

Review 1.  Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.

Authors:  C López-Pedrera; N Barbarroja; G Dorado; E Siendones; F Velasco
Journal:  Leukemia       Date:  2006-05-25       Impact factor: 11.528

2.  Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

Authors:  J D Cash; A M Gader; J da Costa
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

3.  A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.

Authors:  Atsushi Kato; Hina Takano; Ayako Ichikawa; Mayuko Koshino; Aiko Igarashi; Keiichiro Hattori; Kaoru Nagata
Journal:  Thromb Res       Date:  2012-12-08       Impact factor: 3.944

4.  Prediction of venous thromboembolism in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Christine Marosi; Alexandru-Laurentiu Chiriac; Rainer Vormittag; Ralph Simanek; Peter Quehenberger; Christoph Zielinski; Ingrid Pabinger
Journal:  Blood       Date:  2010-09-09       Impact factor: 22.113

Review 5.  The blood coagulation mechanism in multiple myeloma.

Authors:  Maurizio Zangari; Fariba Saghafifar; Paulette Mehta; Bart Barlogie; Louis Fink; Guido Tricot
Journal:  Semin Thromb Hemost       Date:  2003-06       Impact factor: 4.180

6.  Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia.

Authors:  S Pandey; S R Post; D V Alapat; K J Smock; G R Post
Journal:  Int J Lab Hematol       Date:  2012-12-07       Impact factor: 2.877

7.  Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.

Authors:  M C Minnema; R Fijnheer; P G De Groot; H M Lokhorst
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824

Review 8.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Authors:  A Palumbo; S V Rajkumar; M A Dimopoulos; P G Richardson; J San Miguel; B Barlogie; J Harousseau; J A Zonder; M Cavo; M Zangari; M Attal; A Belch; S Knop; D Joshua; O Sezer; H Ludwig; D Vesole; J Bladé; R Kyle; J Westin; D Weber; S Bringhen; R Niesvizky; A Waage; M von Lilienfeld-Toal; S Lonial; G J Morgan; R Z Orlowski; K Shimizu; K C Anderson; M Boccadoro; B G Durie; P Sonneveld; M A Hussein
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  The basis for the increase in factor VIII procoagulant activity during exercise.

Authors:  R G Kopitsky; M E Switzer; R S Williams; P A McKee
Journal:  Thromb Haemost       Date:  1983-02-28       Impact factor: 5.249

10.  ELEVATION OF FACTOR VIII (ANTIHEMOPHILIC FACTOR) DURING PREGNANCY IN NORMAL PERSONS AND IN A PATIENT WITH VON WILLEBRAND'S DISEASE.

Authors:  H S STRAUSS; L K DIAMOND
Journal:  N Engl J Med       Date:  1963-12-05       Impact factor: 91.245

View more
  6 in total

1.  Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release.

Authors:  Antonio Gidaro; Roberto Manetti; Alessandro Palmerio Delitala; Mark Johns Soloski; Giorgio Lambertenghi Deliliers; Dante Castro; Davide Soldini; Roberto Castelli
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

2.  The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.

Authors:  Chuanying Geng; Guangzhong Yang; Huijuan Wang; Zhiyao Zhang; Huixing Zhou; Wenming Chen
Journal:  Biomed Res Int       Date:  2021-05-19       Impact factor: 3.411

3.  Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Zhi Liu; Jing Huang; Qi Zhong; Yanling She; Ruimin Ou; Cheng Li; Rui Chen; Mengdong Yao; Qing Zhang; Shuang Liu
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

4.  Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.

Authors:  Despina Fotiou; Theodoros N Sergentanis; Loula Papageorgiou; Kimon Stamatelopoulos; Maria Gavriatopoulou; Efstathios Kastritis; Theodora Psaltopoulou; Stella Salta; Patrick Van Dreden; Rabiatou Sangare; Annette K Larsen; Evangelos Terpos; Ismail Elalamy; Meletios A Dimopoulos; Grigoris T Gerotziafas
Journal:  Blood Cancer J       Date:  2018-11-07       Impact factor: 11.037

5.  Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance.

Authors:  Pengji Pan; Junxia Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

Review 6.  The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Authors:  Claire Comerford; Siobhan Glavey; John Quinn; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2022-06-23       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.